Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. (2017). Farmeconomia. Health Economics and Therapeutic Pathways, 18(1). https://doi.org/10.7175/fe.v18i1.1332